X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday

X4 Pharmaceuticals (NASDAQ:XFOR) is projected to post its Q4 2025 results before the market opens on Tuesday, March 24th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.36) per share and revenue of $1.6770 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.

X4 Pharmaceuticals Trading Down 3.5%

NASDAQ XFOR opened at $3.56 on Tuesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $10.16. The company has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.61. The firm has a market capitalization of $311.29 million, a PE ratio of -0.35 and a beta of 0.43.

Institutional Trading of X4 Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Bain Capital Life Sciences Investors LLC raised its stake in X4 Pharmaceuticals by 227.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock valued at $31,870,000 after acquiring an additional 5,530,866 shares in the last quarter. Kalehua Capital Management LLC acquired a new position in X4 Pharmaceuticals during the 4th quarter worth $14,891,000. Braidwell LP bought a new position in shares of X4 Pharmaceuticals in the fourth quarter worth $13,476,000. Rosalind Advisors Inc. grew its stake in shares of X4 Pharmaceuticals by 68.7% in the fourth quarter. Rosalind Advisors Inc. now owns 2,605,920 shares of the company’s stock worth $10,424,000 after purchasing an additional 1,061,313 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 9.9% during the fourth quarter. Nantahala Capital Management LLC now owns 2,449,468 shares of the company’s stock valued at $9,798,000 after purchasing an additional 221,118 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on XFOR. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Zacks Research lowered X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Stifel Nicolaus set a $10.00 price target on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Guggenheim assumed coverage on shares of X4 Pharmaceuticals in a research report on Monday, March 9th. They set a “buy” rating and a $12.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.88.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.